Jefferies raised its price target for Bayer to 48.50 euros from 46 euros following the company's Q3 results, while maintaining a 'Hold' rating. The analyst's focus has shifted to the progress of glyphosate litigation settlements, indicating this is a key driver for future performance.
Jefferies increased its price target for Bayer to 48.50 euros from 46 euros after the company's third-quarter financial results. Despite the price target increase, the firm maintained its 'Hold' rating, suggesting that while there's some positive movement, significant upside is not yet anticipated. The analyst's primary focus has shifted to the ongoing glyphosate litigation settlement process, indicating that the resolution of these legal issues is now the most critical factor for Bayer's future valuation and investor sentiment. This suggests that while Q3 results were processed, the market's attention for Bayer will be dominated by legal developments rather than operational performance in the short to medium term. For traders, the key risk and opportunity lies in the unpredictable nature and timing of the glyphosate settlement outcomes.